製品名:tert-Butyl 3-oxocyclobutanecarboxylate

IUPAC Name:tert-butyl 3-oxocyclobutane-1-carboxylate

CAS番号:145549-76-4
分子式:C9H14O3
純度:95%+
カタログ番号:CM202331
分子量:170.21

包装単位 有効在庫 価格(USD) 数量
CM202331-100g in stock ƛǶǶ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:145549-76-4
分子式:C9H14O3
融点:-
SMILESコード:CC(C)(C)OC(=O)C1CC(=O)C1
密度:
カタログ番号:CM202331
分子量:170.21
沸点:230.4°C at 760 mmHg
MDL番号:MFCD12827541
保管方法:Store at 2-8°C.

Category Infos

Cyclobutanes
The molecular structure of cyclobutane has four carbon atoms, and its four carbon atoms are not in the same plane, which is the folded conformation of cyclobutane. Cyclobutane itself is not of commercial or biological interest, but more complex derivatives are important in biology and biotechnology. Currently, nine FDA-approved drugs contain the cyclobutane structure. From the perspective of therapeutic areas, cyclobutyl drugs are mainly distributed in popular areas such as tumors, neurological diseases, infectious diseases, endocrine and metabolic diseases.

Column Infos

DNL343
Denali Therapeutics announces completion of enrollment for regimen G evaluating eIF2B agonist DNL343 in the phase 2/3 HEALEY ALS platform trial. Amyotrophic lateral sclerosis (ALS) causes progressive nerve degeneration in the spinal cord and brain, representing a large unmet medical need. The activation of integrated stress response (ISR) is documented in ALS patients, resulting in the suppression of eukaryotic translation initiation factor 2B (eIF2B) activity, and impaired protein synthesis.
Denali's ALS therapy DNL343 is an investigational small molecule eIF2B activator. It is designed to restore protein synthesis and inhibit ISR pathway in ALS. The compound is found to be generally well-tolerated and support once-daily dosing.